一覧に戻る

タイトル
  • Effective SGLT2 Inhibitor for Patient with Type 2 Diabetes Mellitus (T2DM) and Depression
作成者

Shimizu, E

Takehisa, Y

Bando, Hiroshi

Fujita, M

Kusaka, Y

Yuu, M

権利情報
    • © 2020 Shimizu E, Takehisa Y, Bando H, Fujita M, Kusaka Y, Yuu M. This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
主題
  • Other Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor
  • Other Ipragliflozin L-Proline
  • Other Depression
  • Other Oral Hypoglycemic Agents (OHA)
  • Other Low-Carbohydrate Diet (LCD)
内容注記
Other
  • The case was a 55-year-old female patient with depression for 5 years and type 2 diabetes mellitus (T2DM) for 3 years. She has received anti-depressant and anti-hyperglycemic agents (OHAs). Approximately 1 year ago, her diabetic control became exacerbated without specific triggers. She was started to given Ipragliflozin L-Proline as Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor. After that, her glucose variability and depression had been improved. According to the previous reports, SGLT-2 inhibitors seem to have anti-depression efficacy for diabetes. The case has been followed up in detail, and this report is expected to be a useful reference for diabetes care.
出版者Asploro
日付 Issued 2020-04-14
言語eng
資源タイプjournal article
出版タイプVoR
資源識別子 URI http://repo.lib.tokushima-u.ac.jp/114810
関連
  • isIdenticalTo DOI https://doi.org/10.36502/2020/droa.6160
収録誌情報
    • Diabetes Research : Open Access
    2(S1), 26-32
ファイル
コンテンツ更新日時2020-06-09T04:08:26Z